Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
United States
Biotech
China is no longer licensing 'bargain basement': analyst
The average upfront value for a licensing deal or acquisition increased from $52 million to $172 million between 2022 and early 2026, Evaluate says.
Will Maddox
Feb 24, 2026 5:07pm
Geopolitical pressures didn't dent China biotech deals in 2025
Dec 23, 2025 8:05am
Fierce Pharma
WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg
Dec 4, 2025 8:55am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Fierce Pharma
Massachusetts shed R&D, manufacturing workers in '24: report
Aug 27, 2025 9:34am
Fierce Pharma
New US-EU trade deal includes 15% tariffs on pharmaceuticals
Jul 29, 2025 10:34am
